home / stock / pmn:cc / pmn:cc news

PMN:CC News and Press, Promis Neurosciences Inc. From 05/13/22

Stock Information
Company Name: Promis Neurosciences Inc.
Stock Symbol: PMN:CC
Market: TSXC
Website: promisneurosciences.com
Menu
PMN:CC PMN:CC Quote PMN:CC Short PMN:CC News PMN:CC Articles PMN:CC Message Board
Get PMN:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
PMN:CC - CORRECTION: ProMIS Neurosciences Announces First Quarter 2022 Results

TORONTO, Ontario and CAMBRIDGE, Massachusetts, May 13, 2022 (GLOBE NEWSWIRE) -- There was an error at the end of the first paragraph. March 31, 2021 has been changed to March 31, 2022. There were no other changes to the release. Please find full corrected release below. ProMIS Neurosc...
PMN:CC - ProMIS Holds Annual and Special Meeting of Shareholders All Resolutions Approved

TORONTO, Ontario and CAMBRIDGE, Massachusetts, May 13, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Corporation”) , is pleased to announce the Annual and Special Meeting of Shareholders (the “Meeting&#x...

PMN:CC - ProMIS Neurosciences Announces First Quarter 2022 Results

TORONTO, Ontario and CAMBRIDGE, Massachusetts, May 13, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting ...

PMN:CC - Independent Proxy Advisory Firms, ISS and Glass Lewis, Recommend ProMIS Shareholders Vote FOR All Proposed Items at the Upcoming Annual and Special Meeting of Shareholders

TORONTO, Ontario, May 03, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”) is pleased to announce that leading independent proxy advisory firms, Institutional Shareholder Services Inc. (“ISS”) ...
PMN:CC - ProMIS Neurosciences Reports New Milestones in Potential Therapeutic Approaches for Amyotrophic Lateral Sclerosis (ALS)

TORONTO, Ontario and CAMBRIDGE, MA, April 28, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of potential therapeutics targeting misfolded proteins such as toxic oligomers implicated in ...

PMN:CC - ProMIS appoints experienced industry veteran Larry Altstiel as Chief Medical Officer

TORONTO, Ontario and CAMBRIDGE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the de...

PMN:CC - Argus Research Initiates Equity Report Coverage on ProMIS Neurosciences, Inc. (TSX:PMN & OTCQB: ARFXF)

Argus Research Initiates Equity Report Coverage on ProMIS Neurosciences, Inc. (TSX:PMN & OTCQB: ARFXF) Argus Research Initiates Equity Report Coverage on ProMIS Neurosciences, Inc. (TSX:PMN & OTCQB: ARFXF) PR Newswire NEW YORK , April 18, 2022 /PR...
PMN:CC - ProMIS Files Management Information Circular in Connection with Annual General and Special Meeting of Shareholders

TORONTO, Ontario and CAMBRIDGE, Massachusetts, April 07, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “ Corporation ”) , is pleased to announce it has mailed the Notice of Notice-and-Access (the “...

PMN:CC - ProMIS Neurosciences Presents at the 2022 American Academy of Neurology Annual Meeting

TORONTO, Ontario and CAMBRIDGE, MA, April 07, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in the develo...

PMN:CC - ProMIS Neurosciences to Present at the 10th Annual Neurodegenerative Drug Development Summit

TORONTO, Ontario and CAMBRIDGE, MA , March 24, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in the devel...
Previous 10 Next 10